While Aclaris Therapeutics Inc has overperformed by 53.17%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ACRS rose by 254.72%, with highs and lows ranging from $2.72 to $0.77, whereas the simple moving average jumped by 143.83% in the last 200 days.
On Nov-19-24, Piper Sandler Upgraded Aclaris Therapeutics Inc (NASDAQ: ACRS) to Overweight. A report published by H.C. Wainwright on January 22, 2024, Downgraded its rating to ‘Neutral’ for ACRS. Evercore ISI Initiated an Outperform rating on October 03, 2023, and assigned a price target of $22. Stifel initiated its ‘Buy’ rating for ACRS, as published in its report on December 14, 2022. Goldman’s report from December 01, 2022 suggests a price prediction of $25 for ACRS shares, giving the stock a ‘Buy’ rating. BTIG Research also rated the stock as ‘Buy’.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of Aclaris Therapeutics Inc (ACRS)
Further, the quarter-over-quarter decrease in sales is -53.18%, showing a negative trend in the upcoming months.
To gain a thorough understanding of Aclaris Therapeutics Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -25.83% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 7.03, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and ACRS is recording an average volume of 560.23K. On a monthly basis, the volatility of the stock is set at 13.89%, whereas on a weekly basis, it is put at 20.66%, with a gain of 19.39% over the past seven days. Furthermore, long-term investors anticipate a median target price of $2.50, showing decline from the present price of $3.14, which can serve as yet another indication of whether ACRS is worth investing in or should be passed over.
How Do You Analyze Aclaris Therapeutics Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 4.01%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 70.04% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
ACRS shares are owned by institutional investors to the tune of 70.04% at present.
